SURGEPAYS INC (SURG) Fundamental Analysis & Valuation

NASDAQ:SURG • US86882L2043

Current stock price

0.6468 USD
+0.1 (+17.58%)
At close:
0.6299 USD
-0.02 (-2.61%)
After Hours:

This SURG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SURG Profitability Analysis

1.1 Basic Checks

  • In the past year SURG has reported negative net income.
  • SURG had a negative operating cash flow in the past year.
  • In the past 5 years SURG reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: SURG reported negative operating cash flow in multiple years.
SURG Yearly Net Income VS EBIT VS OCF VS FCFSURG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • With a Return On Assets value of -289.89%, SURG is not doing good in the industry: 95.45% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -289.89%
ROE N/A
ROIC N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURG Yearly ROA, ROE, ROICSURG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SURG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURG Yearly Profit, Operating, Gross MarginsSURG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. SURG Health Analysis

2.1 Basic Checks

  • SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for SURG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SURG Yearly Shares OutstandingSURG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
SURG Yearly Total Debt VS Total AssetsSURG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -13.91, we must say that SURG is in the distress zone and has some risk of bankruptcy.
  • SURG has a worse Altman-Z score (-13.91) than 90.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.91
ROIC/WACCN/A
WACC8.72%
SURG Yearly LT Debt VS Equity VS FCFSURG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.52 indicates that SURG may have some problems paying its short term obligations.
  • SURG has a worse Current ratio (0.52) than 90.91% of its industry peers.
  • SURG has a Quick Ratio of 0.52. This is a bad value and indicates that SURG is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SURG has a Quick ratio of 0.41. This is amonst the worse of the industry: SURG underperforms 95.45% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.41
SURG Yearly Current Assets VS Current LiabilitesSURG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SURG Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.36% over the past year.
EPS 1Y (TTM)24.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%68.66%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y103.17%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year113.46%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SURG Yearly Revenue VS EstimatesSURG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M
SURG Yearly EPS VS EstimatesSURG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. SURG Valuation Analysis

4.1 Price/Earnings Ratio

  • SURG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 11.53 indicates a reasonable valuation of SURG.
  • SURG's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SURG is cheaper than 68.18% of the companies in the same industry.
  • SURG's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 38.20.
Industry RankSector Rank
PE N/A
Fwd PE 11.53
SURG Price Earnings VS Forward Price EarningsSURG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURG Per share dataSURG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SURG Dividend Analysis

5.1 Amount

  • SURG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SURG Fundamentals: All Metrics, Ratios and Statistics

SURGEPAYS INC

NASDAQ:SURG (4/16/2026, 4:30:00 PM)

After market: 0.6299 -0.02 (-2.61%)

0.6468

+0.1 (+17.58%)

Chartmill FA Rating
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)04-14
Earnings (Next)05-11
Inst Owners8.51%
Inst Owner Change0%
Ins Owners30.06%
Ins Owner Change19.16%
Market Cap15.67M
Revenue(TTM)N/A
Net Income(TTM)-42.02M
Analysts80
Price Target9.95 (1438.34%)
Short Float %7.58%
Short Ratio8.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-113.07%
Min EPS beat(2)-150.17%
Max EPS beat(2)-75.97%
EPS beat(4)0
Avg EPS beat(4)-147.6%
Min EPS beat(4)-304.04%
Max EPS beat(4)-60.24%
EPS beat(8)0
Avg EPS beat(8)-211.45%
EPS beat(12)4
Avg EPS beat(12)-3.65%
EPS beat(16)4
Avg EPS beat(16)-210.79%
Revenue beat(2)1
Avg Revenue beat(2)-14.47%
Min Revenue beat(2)-30.02%
Max Revenue beat(2)1.08%
Revenue beat(4)2
Avg Revenue beat(4)-7.34%
Min Revenue beat(4)-30.02%
Max Revenue beat(4)14.43%
Revenue beat(8)3
Avg Revenue beat(8)-9.47%
Revenue beat(12)3
Avg Revenue beat(12)-9.6%
Revenue beat(16)5
Avg Revenue beat(16)-8.22%
PT rev (1m)0%
PT rev (3m)2.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-633.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-30.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.53
P/S 0.31
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)0.06
Fwd EY8.67%
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS2.08
BVpS-0.26
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -289.89%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover3.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.41
Altman-Z -13.91
F-Score2
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.31%
EPS Next Y103.17%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%68.66%
Revenue Next Year113.46%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-76.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-300.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-296.08%
OCF growth 3YN/A
OCF growth 5YN/A

SURGEPAYS INC / SURG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SURGEPAYS INC?

ChartMill assigns a fundamental rating of 0 / 10 to SURG.


Can you provide the valuation status for SURGEPAYS INC?

ChartMill assigns a valuation rating of 3 / 10 to SURGEPAYS INC (SURG). This can be considered as Overvalued.


How profitable is SURGEPAYS INC (SURG) stock?

SURGEPAYS INC (SURG) has a profitability rating of 0 / 10.